Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors

Journal of Alzheimer's Disease

Volumn 55, Issue 2, 2017, Pages 625-644

  Rivero Santana, Amado ^a,b,c   Ferreira, Daniel ^d   Perestelo Pérez, Lilisbeth ^b,c,e   Westman, Eric ^d   Wahlund, Lars Olof ^d   Sarría, Antonio ^b,f   Serrano Aguilar, Pedro ^b,c,e  

^a Canarian Foundation of Health Research (FUNCANIS)   (Spain)

^b Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas REDISSEC   (Spain)

^c Center for Biomedical Research of the Canary Islands (CIBICAN)   (Spain)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Evaluation Unit of the Canary Islands Health Service SESCS   (Spain)

^f Instituto de Salud Carlos III Carlos III Institute for Health   (Spain)

Author keywords

Age; Alzheimer's disease; cerebrospinal fluid markers; confounding factor; disease duration; frontotemporal lobar degeneration; HSROC analysis; Mini Mental State Examination; systematic review

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; FRONTOTEMPORAL DEMENTIA; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BIBLIOGRAPHIC DATABASE; COMPLICATION; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITION DISORDERS; DATABASES, BIBLIOGRAPHIC; DIAGNOSIS, DIFFERENTIAL; FRONTOTEMPORAL LOBAR DEGENERATION; HUMANS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84999266478     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160366     Document Type: Review

References (92)

1. Brunnström H, Gustafson L, Passant U, Englund E (2009) Prevalence of dementia subtypes: A 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr 49, 146-149.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Hall K, Hasegawa K, Hendrie H, HuangY, Jorm A, Menezes PR, Rimmer E, ScazufcaM(2010) Global prevalence of dementia: A Delphi consensus study. Lancet 366, 2112-2117.
3. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
4. Braak H, Zetterberg H, Del Tredici K, Blennow K (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126, 631-641.
5. Onyike CU, Diehl-Schmid J (2013) The epidemiology of frontotemporal dementia. Int Rev Psychiatry 25, 130-137.
6. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC (2011) Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review. J Neurol Neurosurg Psychiatry 82, 476-486.
7. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, Dickson DW (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122, 137-153.
8. Neary D, Snowden J, Gustafson L, Passant U, Stuss D, Black S, Freedman M,Kertesz A, Robert P, Albert M, Boone K, Miller B, Cummings J, Benson D (1998) Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
9. Gustafson L (1987) Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis. Arch Gerontol Geriatr 6, 209-223.
10. No authors listed (1994) Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 57, 416-418.
11. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ (2001) Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58, 1803-1809.
12. Neary D, Snowden J (1996) Fronto-temporal dementia: Nosology, neuropsychology, and neuropathology. Brain Cogn 31 176-187.
13. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477.
14. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update. Acta Neuropathol 119, 1-4.
15. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM,GrossmanM(2011) Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014.
16. Graham A, Davies R, Xuereb J, Halliday G, Kril J, Creasey H, Graham K, Hodges J (2005) Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain 128, 597-605.
17. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG (2005) The evolution and pathology of frontotemporal dementia. Brain 128, 1996-2005.
18. Liscic RM, Storandt M, Cairns NJ, Morris JC (2007) Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. Arch Neurol 64, 535-540.
19. Stopford CL, Snowden JS, Thompson JC, Neary D (2008) Variability in cognitive presentation of Alzheimer's disease. Cortex 44, 185-195.
20. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
21. Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease:Ameta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80, 966-975.
22. Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD (2011) Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis 26, 627-645.
23. Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, BlennowK(2008) Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4, 38-48.
24. Van Harten AC, Kester MI, Visser P-J, Blankenstein MA, Pijnenburg YA, van der Flier WM, Scheltens P (2011) Tau and p-tau as CSF biomarkers in dementia: A meta-analysis. Clin Chem Lab Med 49, 353-366.
25. Tang W, Huang Q, Wang Y, Wang Z-Y, Yao Y-Y (2014) Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies. J Neurol Sci 345, 26-36.
26. Tang W, Huang Q, Yao Y-Y, Wang Y, Wu Y-L, Wang Z-Y (2014) Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm 121, 1541-1553.
27. Dahabreh IJ, Trikalinos TA, Lau J, Schmid C (2012) An empirical assessment of bivariate methods for meta-analysis of test accuracy [Internet]. Agency for Healthcare Research and Quality (US), Rockville, MD, 2012 Nov. Report No.: 12(13)-EHC136-EF.
28. Harbord RM, Whiting P, Sterne JA, Egger M, Deeks JJ, Shang A, Bachmann LM (2008) An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 61, 1095-1103.
29. Rutter CM, Gatsonis CA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 20, 2865-2884.
30. Ferreira D, Perestelo-Pérez L, Westman E, Wahlund L-O, Sarría A, Serrano-Aguilar P (2014) Meta-review of CSF core biomarkers in Alzheimer's disease: The state-of-theart after the new revised diagnostic criteria. Front Aging Neurosci 6, 1-24.
31. Ferreira D, Rivero-Santana A, Perestelo-Pérez L, Westman E, Wahlund L-O, Sarria A, Serrano-Aguilar P (2014) Improving CSF biomarkers' performance for predicting progression from mild cognitive impairment to Alzheimer's disease by considering different confounding factors: A meta-analysis. Front Aging Neurosci 6, 287.
32. Valcarcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P (2014) Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. J Alzheimers Dis 42, 777-788.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
34. Whiting PF, Rutjes AWS,Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MMG, Sterne JAC, Bossuyt PMM (2011) QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155, 529-536.
35. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med 151, 65-94.
36. Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. Int J Surg 8, 336-341.
37. Macaskill P (2004) Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol 57, 925-932.
38. Harbord R, Whiting P (2009) Metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J 9, 211-229.
39. (1998) Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 19, 109-116. Erratum in: Neurobiol Aging 19, 285, 1998.
40. Qizilbash N (2002) Evidenced-based Dementia Practice, Blackwell Publishing, Oxford.
41. Baldeiras I, Santana I, Leitãeo MJ, Ribeiro MH, Pascoal R, Duro D, Lemos R, Santiago B, Almeida MR, Oliveira CR (2015) Cerebrospinal fluid Aβ40 is similarly reduced in patients with frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Sci 358, 308-316.
42. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, Trojanowski J, Lee VM-Y, Grossman M (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70, 1827-1835.
43. Bibl M, Gallus M, Welge V, Esselmann H, Wolf S, Rüther E, Wiltfang J (2012) Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia. J Neural Transm 119, 805-813.
44. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 21, 9-15.
45. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: Abiochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245.
46. Brunnström H, Rawshani N, Zetterberg H, Blennow K, Minthon L, Passant U, EnglundE(2010) Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement 6, 104-109.
47. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, BlennowK, Andreasen N, Hofmann-Kiefer K, DeBernardis J,Kerkman D, McCulloch C,Kohnken R, Padberg F, Pirttilä T, Schapiro MB, Rapoport SI,Möller H-J, Davies P, Hampel H (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 59, 1267-1272.
48. ClarkCM,Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM-Y, Trojanowski JQ (2003) Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60, 1696-1702.
49. De Jong D, Jansen RWMM, Pijnenburg YA, van Geel WJ, Borm GF, Kremer HPH, Verbeek MM (2007) CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 78, 936-938.
50. De Rino F, Martinelli-Boneschi F, Caso F, Zuffi M, Zabeo M, Passerini G, Comi G, Magnani G, Franceschi M (2012) CSF metabolites in the differential diagnosis of Alzheimer's disease from frontal variant of frontotemporal dementia. Neurol Sci 33, 973-977.
51. De Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, Dubois B, Sarazin M (2011) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry 82, 240-246.
52. Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche J-L, Peoc'h K, Schraen S, Buée L, Pasquier F, Hugon J, Touchon J, Lehmann S (2013) Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: The PLM Study. J Alzheimers Dis 34, 297-305.
53. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Coslett HB, Chatterjee A, Gee J, Trojanowski JQ, Lee VM-Y (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 57, 721-729.
54. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies PBK (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61, 95-102.
55. Herbert MK, Aerts MB, Kuiperij HB, Claassen JAHR, Spies PE, Esselink RAJ, Bloem BR, Verbeek MM (2014) Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewybodies from Alzheimer's disease but not other dementias. Alzheimers Dement 10, 448-455.e2.
56. Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang L-S, Van Deerlin V, Lee VM-Y, Trojanowski JQ, Grossman M (2012) Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol 69, 1018-1025.
57. Kapaki E, Paraskevas GP, Papageorgiou SG, Bonakis A, Kalfakis N, Zalonis I, Vassilopoulos D (2008) Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 22, 47-53.
58. Koopman K, Le Bastard N, Martin J-J, Nagels G, De Deyn PP, Engelborghs S (2009) Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 55, 214-218.
59. Paraskevas GP, Kapaki E, Liappas I, Theotoka I, Mamali I, Zournas C, Lykouras L (2005) The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol 18, 163-173.
60. Petzold A, Chapman MD, Schraen S, Verwey NA, Pasquier F, Bombois S, Brettschneider J, Fox NC, von Arnim CAF, Teunissen C, Pijnenburg Y, Riepe MW, Otto M, Tumani H, Scheltens P, Buee L, Rossor MN (2010) An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Exp Neurol 223, 432-438.
61. Pijnenburg YAL, Schoonenboom NSM, Rosso SM, Mulder C, Van Kamp GJ, Van Swieten JC, Scheltens P (2004) CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration. Neurology 62, 1649.
62. Riemenschneider M,Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B, Drzezga A, Jahn T, Förstl H, Kurz A (2002) Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 58, 1622-1628.
63. Schoonenboom NSM, Pijnenburg YAL, Mulder C, Rosso SM, Elk E, Van, Kamp G, van, Swieten J, van, Scheltens P (2004) Amyloid beta (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62, 1580-1584.
64. Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD (2015) Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in theOPTIMAcohort. J Alzheimers Dis 44, 525-539.
65. Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A (2000) Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54, 1960-1964.
66. Sjögren M, Davidsson P, TullbergM,Minthon L,Wallin A, Wikkelso C, Granérus AK, Vanderstichele H, Vanmechelen E, Blennow K (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70, 624-630.
67. Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Schott JM, Blennow K, Eriksdotter M, Zetterberg H (2015) Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain 138, 2716-2731.
68. Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, De Deyn PP, Streffer JR, Mercken M, Engelborghs S (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-β isoforms for early and differential dementia diagnosis. J Alzheimers Dis 45, 813-822.
69. Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, Lee VM-Y, Shaw LM, Trojanowski JQ (2012) CSF biomarkers cutoffs: The importance of coincident neuropathological diseases. Acta Neuropathol 124, 23-35.
70. Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens P, Pijnenburg YA (2010) Additional value of CSF amyloidbeta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 20, 445-452.
71. Holtzman DM (2011) CSF biomarkers for Alzheimer's disease: Current utility and potential future use. Neurobiol Aging 32(Suppl 1), S4-S9.
72. Anoop A, Singh PK, Jacob RS, Maji SK (2010) CSF biomarkers for Alzheimer's disease diagnosis. Int J Alzheimers Dis 2010, 606802.
73. Lorenzi M, Pennec X, Frisoni GB, Ayache N (2015) Disentangling normal aging from Alzheimer's disease in structural magnetic resonance images. Neurobiol Aging 36(Suppl 1), S42-S52.
74. Bouwman FH, Schoonenboom NSM, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM (2009) CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 30, 1895-1901.
75. Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S-K, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, Mulugeta E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Wallin A, Eriksdotter-Jönhagen M, Minthon L, Winblad B, Blennow K, Zetterberg H (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78, 468-476.
76. Li X, Li T-Q, Andreasen N, Wiberg MK, Westman E, Wahlund L-O (2014) The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease. J Intern Med 275, 418-427.
77. Li X, Li T-Q, Andreasen N, Wiberg MK, Westman E, Wahlund L-O (2013) Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD. Sci Rep 3, 1339.
78. Orellana C, Ferreira D, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Soininen H, Lovestone S, Simmons A, Wahlund L-O, Westman E (2016) Measuring global brain atrophy with the brain volume / cerebrospinal fluid index: Normative values, cut-offs, and clinical associations. Neurodegener Dis 16, 77-86.
79. Hales CM, Hu WT (2013) From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. Int Rev Psychiatry 25, 210-220.
80. Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, Nestor PJ, Patterson K (2010) Semantic dementia: Demography, familial factors and survival in a consecutive series of 100 cases. Brain 133, 300-306.
81. Josephs KA, Stroh A, Dugger B, Dickson DW(2009) Evaluation of subcortical pathology and clinical correlations in FTLDU subtypes. Acta Neuropathol 118, 349-358.
82. Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR, Parisi JE, Dickson DW(2006) Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 66, 41-48.
83. Snowden J, Neary D, Mann D (2007) Frontotemporal lobar degeneration: Clinical and pathological relationships. Acta Neuropathol 114, 31-38.
84. Snowden JS, Thompson JC, Stopford CL, RichardsonAMT, Gerhard A, Neary D, Mann DMA (2011) The clinical diagnosis of early-onset dementias: Diagnostic accuracy and clinicopathological relationships. Brain 134, 2478-2492.
85. Knopman DS, Boeve BF, Parisi JE, Dickson DW, Smith GE, Ivnik RJ, Josephs KA, PetersenRC(2005) Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol 57, 480-488.
86. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, Chatterjee A, Hurtig HI, Karlawish JH, Rosen HJ, Van Deerlin V, Lee VM-Y, Miller BL, Trojanowski JQ, Grossman M (2006) Frontotemporal dementia: Clinicopathological correlations. Ann Neurol 59, 952-962.
87. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613.
88. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JCV, Verbeek MM,Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 46, 235-240.
89. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM-Y, Trojanowski JQ (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121, 597-609.
90. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka S-K, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Llado A, Lewczuk P, Li Q-X, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HPM, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7, 386-395.e6.
91. Mioshi E, Hsieh S, Savage S, Hornberger M, Hodges JR (2010) Clinical staging and disease progression in frontotemporal dementia. Neurology 74, 1591-1597.
92. Ferreira D, Jelic V, Cavallin L, Oeksengaard AR, Snaedal J, Høgh P, Bo Andersen B, Naik M, Engedal K, Westman E, Wahlund LO (2016) Electroencephalography is a good complement to currently established dementia biomarkers. Dement Geriatr Cogn Disord 42, 80-92.